Showing 1682 results
-
Press release /ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1] Interim data in over…
-
Featured News /
Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.
-
Story /With extensive experience in public health management, having worked for the International Red Cross, among others, and as a doctor in emergency situations on the ground in Africa and Asia— Ann Aerts discusses the Novartis Foundation's new leprosy strategy.
-
Press release /Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking…
-
Press release /Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
-
Press release /Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients Retrospective contact tracing of former leprosy…
-
Story /Researchers discover that networks of proteins circulating in the blood influence the development and progression of chronic diseases.
-
Story /Novartis drug hunters leverage machine learning and automation to power a faster, smarter way to navigate to new drugs.